147 related articles for article (PubMed ID: 35612551)
1. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer.
Merseburger AS; Roesch MC
Expert Rev Anticancer Ther; 2022 Jul; 22(7):703-715. PubMed ID: 35612551
[TBL] [Abstract][Full Text] [Related]
2. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Schulman C; Cornel E; Matveev V; Tammela TL; Schraml J; Bensadoun H; Warnack W; Persad R; Salagierski M; Gómez Veiga F; Baskin-Bey E; López B; Tombal B
Eur Urol; 2016 Apr; 69(4):720-727. PubMed ID: 26520703
[TBL] [Abstract][Full Text] [Related]
3. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
4. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Sethi R; Sanfilippo N
Clin Interv Aging; 2009; 4():259-67. PubMed ID: 19554097
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
Khan MS; O'Brien A
Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
[TBL] [Abstract][Full Text] [Related]
8. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
9. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
Tunn UW; Gruca D; Bacher P
Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
[TBL] [Abstract][Full Text] [Related]
10. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ
Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
Schmitz-Dräger BJ; Mühlich S; Lange C; Benderska-Söder N; Bismarck E; Starlinger R; Ottillinger B; Hakenberg OW
Urol Int; 2021; 105(5-6):436-445. PubMed ID: 33631760
[TBL] [Abstract][Full Text] [Related]
12. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
Berges R; Bello U
Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
Ohlmann CH; Gross-Langenhoff M
Urol Int; 2018; 100(1):66-71. PubMed ID: 29197875
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
Braeckman J; Michielsen D
Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
[TBL] [Abstract][Full Text] [Related]
15. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
Chang JI; Bucci J
J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
[TBL] [Abstract][Full Text] [Related]
16. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
Kienle E; Lübben G
Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
[TBL] [Abstract][Full Text] [Related]
18. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.
Gravel P; Samland D; Löffler M; Maier S; Panozzo M; Muenzberg M
Adv Ther; 2013 Mar; 30(3):271-85. PubMed ID: 23460040
[TBL] [Abstract][Full Text] [Related]
19. Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K; Sawamura D; Sugawara H; Kato N
Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
[TBL] [Abstract][Full Text] [Related]
20. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
